Clinical Scorecard: Immature granulocytes may signal pediatric lupus activity

At a Glance

Key Highlights

• Among the evaluated white blood cell inflammatory parameters, IG% had the highest discrimination between active disease and remission (AUC 0.90), comparable to ESR (AUC 0.92); the difference was not statistically significant.
• At an IG% cutoff greater than 0.35%, sensitivity was 81%, specificity was 87%, and diagnostic accuracy was 84% in this cohort.
• Median IG% was 0.9% in active disease, compared with 0.2% in remission and 0.2% in healthy controls.
• IG% showed moderate correlations with SLEDAI-2K, clinical SLEDAI-2K, and physician global assessment; conventional markers showed stronger correlations with disease activity.
• IG% rose during early follow-up before declining with inactive disease, and the authors noted that treatment-related changes may complicate longitudinal interpretation.

Guideline-Based Recommendations

Diagnosis

• The study evaluated IG% for distinguishing active pediatric SLE from remission; its greater-than-0.35% cutoff was derived and assessed in the same cohort and requires independent validation.

Management

• The authors describe white blood cell inflammatory parameters, particularly IG%, as potentially complementary to established laboratory markers and clinical assessments, not replacements.

Monitoring & Follow-up

• Interpret longitudinal IG% and other white blood cell inflammatory parameters in the context of treatment exposure, because glucocorticoids and other immunosuppressive therapies may alter leukocyte populations.

Risks

• The study was limited by small sample size, single-center design, lack of independent validation, and absence of established pediatric reference ranges for these parameters.
• Subclinical infections could not be completely excluded, and treatment-related hematologic changes may have influenced longitudinal measurements.

Patient & Prescribing Data

The prospective study included 74 pediatric patients with childhood-onset SLE (43 with active disease and 31 in remission) and 112 age-matched healthy controls.

The article reports no treatment regimen or prescribing comparison. It notes that glucocorticoids can influence circulating immature granulocytes and that other immunosuppressive therapies may alter leukocyte populations.

Clinical Best Practices

• Assess SLE activity using clinical assessments and established laboratory markers; the authors state that white blood cell inflammatory parameters may provide complementary information.
• Do not interpret IG% in isolation: ESR had slightly higher discriminatory performance, and complement C3 showed stronger correlations with disease activity.
• Consider treatment exposure when interpreting changes in IG% during follow-up.
• Recognize that the reported IG% cutoff and performance require validation in larger, multicenter studies.

Related Resources & Content

• ACR Open Rheumatology study, as described in the supplied article